Value-Based Contracting Bill Aims For Bipartisan Political Support
(2/3, Michael Cipriano, Pink Sheet) reports “...[PhRMA] has not yet directly endorsed the bill. The group told the Pink Sheet in a statement that it is still reviewing the bill but added that ‘we have long said that we need to find new innovative ways to pay for medicines, including advancing more value-based contracts.’...Eli Lilly & Co., which has long advocated for legislative and regulatory changes to support value-based arrangements, told the Pink Sheet in a statement that the company supports the Cassidy/Warner bill. ‘We believe this bill is a major step in the right direction,’ a Lilly spokesperson said.” Paid Subscription Required
Assessing Value of Novel Therapies in the Changing Oncology Landscape
(2/4, Journal of Clinical Pathways) reports “...[Christian Frois, PhD] and colleagues found that 83% of respondents' organizations employed some form of internal clinical pathways. However, only 25% of these integrated in their EMR systems saw pathways as significantly affecting clinicians' drug treatment decision-making. Furthermore, providers reported the desire for patient-level tools to make more appropriate drug decisions, rather than value frameworks.” Full
Novartis Spend on Digital and Data ‘In the 100s of Millions'
(2/1, Anna Smith, PharmaTimes) reports “...With around 250 data scientists working within the Novartis Institutes for BioMedical Research, the Swiss drug maker says it plans to revolutionise the way data is used to effectively treat patients, through techniques such as managing more than 500 clinical trials from its Sense control room in Basel, and a partnership with the Big Data Institute - an alliance using artificial intelligence to understand complex diseases and improve drug development.” Full
Plans, Medicare Advocates Concerned By Timeline Of VBID Expansion
(2/1, Chelsea Cirruzzo, InsideHealthPolicy.com) reports “...Andrew Fish of Tufts Health called the expanded demo exciting and reflective of opportunities plans were hoping to see in future models -- particularly the addition of socioeconomic benefits. However, he cautioned that implementation is easier said than done for plans and often requires a new workflow, a new data set, and new management...He also called the timeline for applications questionable, saying that there are a lot of new opportunities available, but it may take time for plans to craft thorough applications.” Paid Subscription Required
Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective
Christian Frois, PhD, et al.
February 2019, Journal of Managed Care & Specialty Pharmacy
Eliciting Patient-Important Outcomes Through Group Brainstorming: When Is Saturation Reached?
Marianna LaNoue, et al.
February 4, 2019, Journal of Patient-Reported Outcomes
Meta-Analysis for Medical Decisions
National Bureau of Economic Research